netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Lawrence Cohen appointed as CEO of Glycotest Inc.

Dec 16, 2015
-
Glycotest, News, RNS Announcements
RNS Number : 1865J
NetScientific PLC
16 December 2015

 

NetScientific appoints diagnostics leader Lawrence Cohen
as CEO of Glycotest Inc.

 

London, UK – 16 December 2015 – NetScientific plc (AIM: NSCI, “NetScientific” or the “Group”), the transatlantic biomedical and healthcare technology group, today announces the appointment of Lawrence ‘Larry’ Cohen as CEO of its portfolio company, Glycotest, effective from 4 January 2016.

 

Glycotest is a molecular diagnostics company commercializing clinical laboratory testing services which reduce mortality and increase survival for patients at risk of liver cancers and fibrosis-cirrhosis. Larry’s appointment will help accelerate the development and commercialisation of Glycotest’s novel non-invasive blood tests.

 

Larry brings over 30 years’ experience in the medical device and diagnostics sector. His most recent role was CEO of Exalenz Bioscience, a medical device company for the diagnosis and management of digestive tract and liver diseases.  Previously, Larry worked in several senior level roles within the diagnostics sector, including as CEO of SenGenix, CEO of Hemosense and President of International Technidyne Corp. which grew 3 times under his leadership. Formerly, Larry was VP marketing and sales for global diagnostic companies including Beckman Instruments, Fisher Medical Group and Ortho Clinical Diagnostics, a Johnson & Johnson company.

 

Francois Martelet, Group CEO of NetScientific, commented: “Larry Cohen is a seasoned executive in the world of diagnostics, who will be instrumental in driving the delivery of Glycotest’s novel tests. Our focus as a Group is to move our portfolio companies to commercialisation. Larry’s appointment follows on from our recent appointment of Gene Walther as CEO of Vortex BioSciences, both will play a crucial part in our Diagnostics franchise once they start in their roles on 4 January 2016.”

 

Larry Cohen said: “Glycotest has an important diagnostic testing capability which has the potential to make a significant impact on patients’ lives. NetScientific and the Glycotest team have developed an extraordinary test; it is my aim to continue this momentum by bringing this test to the market.”

 

                                                                                                – Ends –

Contact Details

NetScientific    Tel. +44 (0) 20 3514 1800

François R. Martelet, M.D., CEO

Peter Thoms, CFO

 

 

 

Investec (NOMAD and broker) 

Gary Clarence/Daniel Adams

Tel + 44 (0) 20 7597 4000

 

Instinctif Partners  Tel. +44 (0) 20 7457 2020

email: netscientific@instinctif.com

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

 

 

 

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

About Glycotest 

Glycotest is a molecular diagnostics company commercializing clinical laboratory testing services to reduce mortality and increase survival for patients at risk for liver cancers and fibrosis-cirrhosis. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay methodology that exploit novel sugar-based disease signal chemistry. Glycotest initially will make its testing services available to physicians who care for at-risk patients to help them identify those likely to have curable early-stage disease. Ultimately Glycotest intends to develop its tests into tools for prediction of therapeutic response and clinical outcome.

Glycotest was founded in 2012 on technology that originated at the Baruch S. Blumberg Institute (the Hepatitis B Foundation’s research organization) and Drexel University College of Medicine in the laboratories of Dr. Timothy Block and Professor Anand Mehta. www.glycotest.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCDGBDDUSBBGUU

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
WANDA signs contract with HRS
NEXT POST →
Appointment of Gene Walther as Vortex CEO

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Lawrence Cohen appointed as CEO of Glycotest Inc. - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT